Copyright
        ©The Author(s) 2025.
    
    
        World J Gastrointest Oncol. Sep 15, 2025; 17(9): 106116
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106116
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106116
            Table 1 Healthcare payment and survival outcome of esophageal cancer
        
    | Payment situation | Prognosis | Potential major explanations | 
| Basic medical insurance | ||
| UEBMI vs URRBMI | Unfavorable | Less TNM stage I-II diseases, and more TNM stage IV diseases in UEBMI subset. More patients with TNM stage IV esophageal cancers were willing to undertake active therapies if supported by UEBMI | 
| OOP rate | ||
| > 60% vs ≤ 60% | Favorable | More TNM stage I-II diseases, and less TNM stage IV diseases in high OOP subset. Potentially higher education level, better awareness of cancer prevention and control, more accessible healthcare resources, and better affordable finance | 
| Per 10% incremental WTP | ||
| UEBMI subset | Favorable | Increasing the accessibility of active therapies in UEBMI subset which had more patients with advanced diseases | 
| OOP rate > 60% subset | Unfavorable | As a post-hoc situation, associated with advanced stages migrating correspondingly | 
- Citation: Li ZY, Wang R, Chen XZ, SIGES Research Group. Associations among healthcare insurance, tumor-node-metastasis stage and cancer survival: More to be understood. World J Gastrointest Oncol 2025; 17(9): 106116
 - URL: https://www.wjgnet.com/1948-5204/full/v17/i9/106116.htm
 - DOI: https://dx.doi.org/10.4251/wjgo.v17.i9.106116
 
